Wird geladen...
Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
BACKGROUND: Population‐based studies previously showed an improvement in overall survival (OS) for patients with diffuse large B‐cell lymphoma (DLBCL) who received chemoimmunotherapy with rituximab. However, there is limited data (especially at the population level) that show a similar trend in OS i...
Gespeichert in:
| Veröffentlicht in: | Cancer Med |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7402846/ https://ncbi.nlm.nih.gov/pubmed/32558356 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3237 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|